The hazard of death was 14% lower in CCA patients harboring FGFR2 fusion when compared to those without FGFR2 alteration, whereas the 95% CI (0.59–1.27) covered 1 (Figure S1a). The gene discussed is FGFR2; the disease is cholangiocarcinoma.